Table 3. Treatment efficacy and safety estimates from Bayesian network meta-analyses.
|
Clinical remission | |||||||||||||
| 5-ASA 4 g/d | |||||||||||||
| 1.02 (0.68, 1.45) | 5-ASA 1.5 to 2.0 g/d | ||||||||||||
| 1.16 (0.77, 1.71) | 1.15 (0.79, 1.61) | 5-ASA 1 g/d | |||||||||||
| 2.27 (1.35, 3.54) | 2.26 (1.35, 3.62) | 2.00 (1.15, 3.20) | Budesonide ≥ 4 mg/d | ||||||||||
| 2.84 (1.78, 4.17) | 2.83 (1.76, 4.40) | 2.50 (1.58, 3.98) | 1.30 (0.80, 1.98) | Budesonide 2 to 2.3 mg/d | |||||||||
| 4.59 (1.90, 9.75) | 4.57 (1.85, 9.60) | 4.03 (1.69, 8.66) | 2.06 (0.90, 4.12) | 1.64 (0.71, 3.29) | Budesonide 0.5 mg/d | ||||||||
| 1.00 (0.58, 1.63) | 1.00 (0.58, 1.64) | 0.88 (0.51, 1.39) | 0.46 (0.24, 0.81) | 0.36 (0.20, 0.59) | 0.26 (0.09, 0.57) | BDP 3 mg/d | |||||||
| 1.18 (0.44, 2.54) | 1.17 (0.43, 2.47) | 1.03 (0.38, 2.21) | 0.54 (0.20, 1.22) | 0.42 (0.16, 0.88) | 0.30 (0.08, 0.77) | 1.24 (0.42, 2.89) | Betamethasone 5 mg/d | ||||||
| 1.87 (0.52, 4.68) | 1.85 (0.51, 4.45) | 1.61 (0.48, 3.91) | 0.87 (0.23, 2.24) | 0.68 (0.18, 1.76) | 0.48 (0.10, 1.42) | 1.95 (0.52, 5.27) | 1.91 (0.39, 5.79) | Hydrocortisone 356 mg/d | |||||
| 4.00 (1.99, 7.59) | 4.01 (1.89, 7.83) | 3.54 (1.66, 7.13) | 1.84 (0.85, 3.85) | 1.42 (0.75, 2.59) | 1.01 (0.35, 2.41) | 4.21 (1.86, 8.61) | 4.09 (1.28, 10.35) | 2.94 (0.68, 8.61) | Hydrocortisone 100 mg/d | ||||
| 1.15 (0.49, 2.36) | 1.14 (0.48, 2.36) | 1.00 (0.42, 2.01) | 0.53 (0.21, 1.13) | 0.41 (0.18, 0.84) | 0.29 (0.08, 0.73) | 1.16 (0.54, 2.24) | 1.17 (0.33, 3.12) | 0.82 (0.18, 2.35) | 0.32 (0.10, 0.70) | Prednisolone ≥30 mg/d | |||
| 2.34 (1.28, 3.92) | 2.30 (1.37, 3.62) | 2.04 (1.22, 3.23) | 1.07 (0.55, 1.87) | 0.84 (0.46, 1.36) | 0.59 (0.22, 1.25) | 2.45 (1.25, 4.44) | 2.30 (0.96, 4.66) | 1.68 (0.47, 4.43) | 0.64 (0.27, 1.20) | 2.33 (0.89, 5.05) | Prednisolone 20 to 25 mg/d | ||
| 0.39 (0.05, 1.11) | 0.39 (0.05, 1.16) | 0.35 (0.05, 1.08) | 0.18 (0.02, 0.57) | 0.14 (0.02, 0.44) | 0.10 (0.01, 0.34) | 0.40 (0.06, 1.26) | 0.40 (0.04, 1.45) | 0.29 (0.03, 1.10) | 0.11 (0.01, 0.37) | 0.39 (0.05, 1.24) | 0.18 (0.02, 0.57) | 5-ASA 1.5 to 2.0 g/d + BDP 3 mg/d | |
| 6.35 (4.33, 9.26) | 6.30 (4.33, 9.08) | 5.57 (3.70, 8.23) | 2.88 (1.99, 4.26) | 2.30 (1.50, 3.47) | 1.60 (0.69, 3.17) | 6.69 (3.78, 11.54) | 6.52 (2.47, 14.58) | 4.60 (1.31, 12.06) | 1.75 (0.80, 3.20) | 6.38 (2.65, 13.08) | 2.88 (1.68, 4.84) | 29.22 (5.15, 117.49) | Placebo |
| Endoscopic remission | |||||||||||||
| 5-ASA 4 g/d | |||||||||||||
| 1.12 (0.68, 1.73) | 5-ASA 1.5 to 2.0 g/d | ||||||||||||
| 1.11 (0.65, 1.76) | 1.01 (0.64, 1.48) | 5-ASA 1 g/d | |||||||||||
| 2.22 (1.10, 4.11) | 2.04 (1.01, 3.46) | 2.07 (1.00, 3.74) | Budesonide ≥4 mg/d | ||||||||||
| 1.60 (0.89, 2.66) | 1.48 (0.76, 2.53) | 1.50 (0.81, 2.59) | 0.77 (0.37, 1.48) | Budesonide 2 to 2.3 mg/d | |||||||||
| 5.58 (1.66, 14.37) | 5.13 (1.49, 12.76) | 5.19 (1.55, 12.82) | 2.58 (0.91, 5.92) | 3.57 (1.20, 8.89) | Budesonide 0.5 mg/d | ||||||||
| 1.27 (0.60, 2.51) | 1.17 (0.54, 2.16) | 1.19 (0.54, 2.33) | 0.61 (0.26, 1.27) | 0.83 (0.37, 1.64) | 0.29 (0.08, 0.77) | BDP 3 mg/d | |||||||
| 3.49 (0.91, 9.87) | 3.33 (0.75, 10.20) | 3.33 (0.76, 9.54) | 1.77 (0.35, 6.08) | 2.39 (0.54, 7.42) | 0.85 (0.13, 3.18) | 3.18 (0.60, 10.50) | Hydrocortisone 100 mg/d | ||||||
| 1.89 (0.76, 3.94) | 1.73 (0.71, 3.41) | 1.76 (0.71, 3.53) | 0.92 (0.35, 2.10) | 1.20 (0.58, 2.22) | 0.43 (0.10, 1.06) | 1.58 (0.68, 3.36) | 0.77 (0.12, 2.58) | Prednisolone ≥30 mg/d | |||||
| 1.55 (0.79, 2.84) | 1.40 (0.74, 2.34) | 1.43 (0.74, 2.42) | 0.75 (0.32, 1.51) | 1.01 (0.49, 1.86) | 0.36 (0.09, 1.00) | 1.36 (0.51, 2.98) | 0.63 (0.12, 1.94) | 0.94 (0.34, 2.16) | Prednisolone 20 to 25 mg/d | ||||
| 0.72 (0.44, 1.13) | 0.66 (0.44, 0.97) | 0.67 (0.43, 1.02) | 0.35 (0.21, 0.56) | 0.48 (0.26, 0.81) | 0.17 (0.05, 0.40) | 0.63 (0.30, 1.17) | 0.29 (0.06, 0.84) | 0.44 (0.18, 0.91) | 0.51 (0.26, 0.91) | 5-ASA 1.5 to 2.0 g/d + BDP 3 mg/d | |||
| 5.36 (3.26, 8.38) | 4.89 (3.22, 7.16) | 4.97 (3.21, 7.51) | 2.55 (1.55, 4.12) | 3.53 (1.90, 5.95) | 1.23 (0.39, 2.98) | 4.66 (2.21, 8.67) | 2.18 (0.47, 6.21) | 3.25 (1.35, 6.73) | 3.76 (1.92, 6.76) | 17.00 （5.21, 41.18) | Placebo | ||
| Histopathological remission | |||||||||||||
| 5-ASA 4 g/d | |||||||||||||
| 1.05 (0.52, 1.90) | 5-ASA 1.5 to 2.0 g/d | ||||||||||||
| 1.44 (0.72, 2.66) | 1.42 (0.78, 2.26) | 5-ASA 1 g/d | |||||||||||
| 1.67 (0.79, 3.41) | 1.73 (0.73, 3.82) | 1.26 (0.50, 2.84) | Budesonide 2 to 2.3 mg/d | ||||||||||
| 1.25 (0.14, 4.38) | 1.37 (0.14, 4.63) | 0.96 (0.10, 3.33) | 0.75 (0.11, 2.40) | Prednisolone ≥30 mg/d | |||||||||
| 1.55 (0.56, 3.90) | 1.50 (0.62, 3.18) | 1.12 (0.40, 2.79) | 1.00 (0.32, 2.25) | 2.77 (0.29, 10.19) | Prednisolone 20 to 25 mg/d | ||||||||
| 8.64 (3.68, 20.26) | 8.56 (3.79, 17.29) | 6.33 (2.67, 13.32) | 5.75 (1.87, 13.60) | 14.68 (1.71, 62.94) | 6.82 (1.93, 18.55) | Placebo | |||||||
| Adverse events | |||||||||||||
| 5-ASA 4 g/d | |||||||||||||
| 0.74 (0.30, 1.43) | 5-ASA 1.5 to 2.0 g/d | ||||||||||||
| 0.75 (0.27, 1.55) | 1.05 (0.54, 1.66) | 5-ASA 1 g/d | |||||||||||
| 0.60 (0.24, 1.15) | 0.90 (0.34, 1.85) | 0.91 (0.33, 2.13) | Budesonide ≥4 mg/d | ||||||||||
| 0.73 (0.35, 1.32) | 1.11 (0.45, 2.19) | 1.12 (0.46, 2.42) | 1.31 (0.69, 2.29) | Budesonide 2 to 2.3 mg/d | |||||||||
| 0.71 (0.22, 1.62) | 1.08 (0.28, 2.71) | 1.09 (0.30, 2.73) | 1.25 (0.45, 2.69) | 1.01 (0.36, 2.14) | Budesonide 0.5 mg/d | ||||||||
| 0.65 (0.20, 1.64) | 0.91 (0.41, 1.75) | 0.91 (0.38, 1.82) | 1.21 (0.36, 3.22) | 0.94 (0.31, 2.27) | 1.13 (0.26, 3.21) | BDP 3 mg/d | |||||||
| 0.71 (0.17, 1.82) | 1.05 (0.29, 2.74) | 1.06 (0.27, 2.82) | 1.31 (0.33, 3.54) | 1.02 (0.29, 2.75) | 1.24 (0.26, 3.85) | 1.31 (0.29, 3.90) | Betamethasone 5 mg/d | ||||||
| 0.91 (0.11, 3.12) | 1.29 (0.20, 4.41) | 1.23 (0.23, 4.11) | 1.67 (0.19, 6.05) | 1.32 (0.18, 4.66) | 1.51 (0.16, 5.50) | 1.54 (0.23, 5.58) | 1.68 (0.16, 6.31) | Hydrocortisone 356 mg/d | |||||
| 0.47 (0.13, 1.07) | 0.71 (0.18, 1.70) | 0.71 (0.20, 1.90) | 0.85 (0.23, 2.04) | 0.64 (0.24, 1.25) | 0.80 (0.18, 2.18) | 0.88 (0.18, 2.35) | 0.87 (0.16, 2.63) | 0.98 (0.11, 3.46) | Hydrocortisone 100 mg/d | ||||
| 0.82 (0.17, 2.56) | 1.17 (0.31, 3.40) | 1.18 (0.27, 3.44) | 1.49 (0.28, 4.71) | 1.15 (0.27, 3.29) | 1.38 (0.24, 4.61) | 1.35 (0.40, 3.84) | 1.50 (0.24, 4.98) | 1.63 (0.16, 6.52) | 2.17 (0.36, 6.96) | Prednisolone ≥30 mg/d | |||
| 1.23 (0.39, 2.88) | 1.72 (0.77, 3.33) | 1.73 (0.75, 3.49) | 2.25 (0.74, 5.22) | 1.76 (0.61, 4.02) | 2.11 (0.55, 6.25) | 2.14 (0.76, 5.19) | 2.13 (0.61, 5.80) | 2.46 (0.34, 8.36) | 3.30 (0.82, 9.67) | 2.08 (0.46, 6.10) | Prednisolone 20 to 25 mg/d | ||
| 0.52 (0.06, 1.77) | 0.72 (0.13, 2.23) | 0.73 (0.12, 2.30) | 0.97 (0.12, 3.54) | 0.76 (0.11, 2.69) | 0.91 (0.11, 3.55) | 0.83 (0.15, 2.80) | 1.03 (0.09, 4.22) | 1.01 (0.06, 4.57) | 1.51 (0.15, 5.77) | 0.83 (0.10, 3.66) | 0.48 (0.06, 1.69) | 5-ASA 1.5 to 2.0 g/d + BDP 3 mg/d | |
| 0.88 (0.42, 1.53) | 1.30 (0.59, 2.34) | 1.31 (0.59, 2.57) | 1.56 (0.84, 2.69) | 1.25 (0.63, 2.08) | 1.46 (0.59, 3.31) | 1.62 (0.56, 3.76) | 1.63 (0.46, 4.25） | 1.90 (0.28, 7.09) | 2.34 (0.81, 5.77) | 1.54 (0.36, 4.34) | 0.84 (0.30, 1.81) | 3.15 (0.47, 11.43) | Placebo |
The efficacy was estimated in the triangle, comparing column-defining with row-defining treatments. The estimates of effects were summarized as odds ratios (ORs) with their corresponding 95% credible intervals (CrIs) respectively. For the efficacy assessment, ORs greater than 1 favor the column-defining treatment, while for adverse effects, ORs greater than 1 favor the row-defining treatment. Results with significant statistical differences are shown in bold.5-ASA, 5-aminosalicylic acid; BDP, beclomethasone dipropionate.